Poggi-Travert F, Fournier B, Poll-The B T, Saudubray J M
Department of Pediatrics, Hopital des Enfants-Malades, Paris, France.
J Inherit Metab Dis. 1995;18 Suppl 1:1-18. doi: 10.1007/BF00711425.
At least 21 genetic disorders have now been found that are linked to peroxisomal dysfunction. Whatever the genetic defect might be, peroxisomal disorders should be considered in various clinical conditions, dependent on the age of onset. The prototype of peroxisomal disorders is represented by 'classical' Zellweger syndrome (ZS) which is the most severe disorder combining all the characteristic symptoms. ZS is characterized by the association of errors of morphogenesis, severe neurological dysfunction, neurosensory defects, regressive changes, hepatodigestive involvement with failure to thrive, usually early death, and absence of recognizable liver peroxisomes. Other peroxisomal disorders (pseudo-Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), pseudo-neonatal adrenoleukodystrophy, rhizomelic chondrodysplasia punctata (RCDP), and hyperpipecolic acidaemia) share some of these symptoms, but with varying organ involvement, severity of dysfunction, and duration of survival. The diagnosis should not cause difficulty when all the characteristic manifestations are present. Depending on the main presenting sign, peroxisomal disorders in neonates should be suspected in two categories of circumstances: polymalformative syndrome with craniofacial dysmorphism, and severe neurological dysfunction. During the first 6 months of life, the predominant symptoms may be hepatomegaly, prolonged jaundice, liver failure, anorexia, vomiting and diarrhoea leading to failure to thrive resembling a malabsorption syndrome; severe psychomotor retardation, hearing loss and ocular abnormalities become evident. Beyond 4 years of age, behavioural changes, intellectual deterioration, visual impairment and gait abnormalities may be the presenting symptoms. Independently of the clinical symptoms and age of onset, most peroxisomal disorders described so far can be clinically screened by recordings of electroretinogram, visual-evoked responses, and brain auditory-evoked responses, which are almost always abnormal. Nine of the 17 peroxisomal disorders with neurological involvement are associated with an accumulation of very long-chain fatty acids (VLCFA), which suggests that assay of plasma VLCFA should be used as a primary test. However, assays of plasma phytanic acid and plasma/urine bile acid intermediates should also be performed in view of the recent reports of atypical chondrodysplasia variants (without rhizomelic shortening) and isolated trihydroxycholestanoic aciduria. The differential diagnoses in various clinical conditions and age periods are discussed.
目前已发现至少21种与过氧化物酶体功能障碍相关的遗传疾病。无论基因缺陷如何,在不同的临床情况下,都应根据发病年龄考虑过氧化物酶体疾病。过氧化物酶体疾病的典型代表是“经典型”泽尔韦格综合征(ZS),它是最严重的疾病,合并了所有特征性症状。ZS的特征是形态发生错误、严重神经功能障碍、神经感觉缺陷、退行性变化、肝消化受累及生长发育迟缓、通常早亡,以及肝脏中无法识别出过氧化物酶体。其他过氧化物酶体疾病(假性泽尔韦格综合征、新生儿肾上腺脑白质营养不良(NALD)、假性新生儿肾上腺脑白质营养不良、肢根型点状软骨发育不良(RCDP)和高哌可酸血症)也有一些这些症状,但器官受累程度、功能障碍严重程度和存活时间各不相同。当所有特征性表现都存在时,诊断不应困难。根据主要表现体征,在两类情况下应怀疑新生儿过氧化物酶体疾病:伴有颅面畸形的多畸形综合征和严重神经功能障碍。在生命的前6个月,主要症状可能是肝肿大、黄疸持续时间延长、肝功能衰竭、厌食、呕吐和腹泻,导致生长发育迟缓,类似吸收不良综合征;严重的精神运动发育迟缓、听力丧失和眼部异常变得明显。4岁以后,行为改变、智力衰退、视力损害和步态异常可能是主要症状。与临床症状和发病年龄无关,目前描述的大多数过氧化物酶体疾病都可以通过记录视网膜电图、视觉诱发电位和脑听觉诱发电位进行临床筛查,这些检查几乎总是异常的。17种伴有神经受累的过氧化物酶体疾病中有9种与极长链脂肪酸(VLCFA)的积累有关,这表明血浆VLCFA检测应作为主要检测方法。然而,鉴于最近关于非典型软骨发育不良变体(无肢根缩短)和孤立性三羟基胆甾烷酸尿症的报道,也应进行血浆植烷酸和血浆/尿液胆汁酸中间体的检测。本文讨论了不同临床情况和年龄阶段的鉴别诊断。